

## 2013 BIOTECHNOLOGY RESEARCH REVIEW



**BIO069E**  
**December 2013**

Various Analysts  
***Project Analyst***

ISBN: 1-56965-646-0

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 2013 BIOTECHNOLOGY RESEARCH REVIEW	2
FOREWORD	2
CHAPTER 2 RNAI TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO127A)	4
INTRODUCTION	4
STUDY GOALS AND OBJECTIVES	4
REASONS FOR DOING THE STUDY	4
SCOPE OF REPORT	5
METHODOLOGY AND INFORMATION SOURCES	5
INTENDED AUDIENCE	5
ANALYST CREDENTIALS	5
RELATED REPORTS	5
SUMMARY	6
<i>TABLE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>FIGURE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 (\$ MILLIONS)</i>	7
OVERVIEW OF RNAI TECHNOLOGIES	7
RNAI DISCOVERY	9
RNAI GENE-SILENCING MECHANISM	9
<i>FIGURE 2 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM</i>	9
MICRORNA	10
<i>TABLE 2 MICRORNA DATABASES</i>	11
<i>TABLE 3 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION</i>	12
RNAI APPLICATIONS	12
RNAI RESEARCH TOOLS AND REAGENTS	12
RNAI DRUG DEVELOPMENT	12
RNAi Drug Delivery	13
Stability	13
Size Limitation	13
Cellular Uptake	14
Immune Response Activation	14
Targeting	14
RNAi Drug Design	14
RNAI DIAGNOSTICS: MICRORNA DIAGNOSTICS	15
RNAI IN AGRICULTURE	15
RNAI MARKET OVERVIEW	15
<i>TABLE 4 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/\$ MILLIONS/\$ BILLIONS)</i>	16
RNAI AS A POSSIBLE TECHNOLOGICAL PREMATUREITY	17
MERCK AND RNAI	17
Acquisition of Sirna Therapeutics	17
RNAi Research Center Closure	18
Merck's Continued Interest in RNAi	18
ROCHE AND RNAI	18
Alliance with Alnylam	18

<b>TOPIC</b>	<b>PAGE NO.</b>
Alliance Termination	19
Transfers RNAi Assets to Arrowhead Research	19
PFIZER AND RNAI	19
NOVARTIS AND RNAI	19
ABBOTT AND RNAI	20
ALNYLAM AND RNAI	20
Alnylam and Tekmira	20
Kyowa Hakko, Ascleptis and Sanofi Alliances	20
Future of Alnylam	21
TEKMIRA'S PARTNERS	21
DICERNA PHARMACEUTICALS FINANCING	22
REGULUS INITIAL PUBLIC OFFERING	22
MARINA-DEBIOPHARM PARTNERSHIP	22
INTELLECTUAL PROPERTY IN THE RNAI MARKETPLACE	22
<i>TABLE 5 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS</i>	23
U.S. SUPREME COURT: HUMAN GENES CANNOT BE PATENTED	23
PATENT ANALYSIS	25
<i>TABLE 6 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEYWORDS, AS OF AUG. 2013</i>	25
<i>TABLE 7 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUG. 2013</i>	26
RNAI MARKETPLACE FUTURE	26
CHAPTER 3 NEXT GENERATION SEQUENCING: EMERGING CLINICAL APPLICATIONS AND GLOBAL MARKETS (REPORT BIO126A)	29
INTRODUCTION	29
STUDY GOALS AND OBJECTIVES	29
REASONS FOR DOING THE STUDY	29
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	30
SCOPE AND FORMAT	30
METHODOLOGY	31
INFORMATION SOURCES	31
RELATED BCC REPORTS	31
ANALYST CREDENTIALS	32
EXECUTIVE SUMMARY	32
<i>TABLE 8 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 (\$ MILLIONS)</i>	33
<i>FIGURE 3 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 (\$ MILLIONS)</i>	33
OVERVIEW	34
<i>TABLE 9 REPORT SCOPE</i>	35
CLINICAL NEXT GENERATION SEQUENCING MARKET	35
<i>TABLE 10 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)</i>	36
DRIVING FORCES OF THE GROWTH OF CLINICAL NEXT GENERATION SEQUENCING	37
TECHNOLOGY DRIVERS	37
<i>TABLE 11 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING</i>	37

<b>TOPIC</b>	<b>PAGE NO.</b>
MARKET DRIVERS	38
<i>TABLE 12 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES</i>	39
CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS	40
<i>TABLE 13 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS</i>	40
CLINICAL NEXT GENERATION SEQUENCING INDUSTRY	41
<i>TABLE 14 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR</i>	41
CHAPTER 4 BIOINFORMATICS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO051B)	44
INTRODUCTION	44
STUDY GOALS AND OBJECTIVES	44
REASONS FOR DOING THE STUDY	44
SCOPE OF REPORT	44
INTENDED AUDIENCE	45
METHODOLOGY AND INFORMATION SOURCES	45
ANALYST CREDENTIALS	46
RELATED BCC REPORTS	46
SUMMARY	46
<i>TABLE 15 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	47
<i>FIGURE 4 BIOINFORMATICS MARKET BY REGION, 2011-2017 (\$ MILLIONS)</i>	47
INTRODUCTION TO BIOINFORMATICS	49
<i>FIGURE 5 BIOINFORMATIC RELATIONSHIP TO 'OMIC TECHNOLOGIES</i>	50
BIOLOGICAL DATA SOURCES	50
BIOINFORMATICS IN TRANSLATIONAL MEDICINE: A SYSTEM BIOLOGY APPROACH	51
<i>FIGURE 6 SYSTEMS BIOLOGY PRINCIPAL APPROACHES</i>	52
BIOINFORMATICS IN DRUG DEVELOPMENT	53
MARKET DRIVERS	54
MARKET RESISTORS	55
CURRENT MARKET	56
MARKET BY REGION	56
<i>TABLE 16 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	56
MARKET BY CATEGORY	57
<i>TABLE 17 BIOINFORMATICS MARKET BY CATEGORY, THROUGH 2017 (\$ MILLIONS)</i>	57
MARKET BY APPLICATION	58
<i>TABLE 18 BIOINFORMATICS MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)</i>	59
CHAPTER 5 METABOLOMICS: TECHNOLOGIES AND GLOBAL MARKETS (REPORT BIO055A)	61
INTRODUCTION	61
STUDY GOALS AND OBJECTIVES	61
REASONS FOR DOING THIS STUDY	61
SCOPE AND FORMAT	62
METHODOLOGY AND INFORMATION SOURCES	62
INTENDED AUDIENCE	62
ANALYST CREDENTIALS	62
RELATED REPORTS	63

<b>TOPIC</b>	<b>PAGE NO.</b>
SUMMARY	63
<i>TABLE 19 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, THROUGH 2017 (\$ MILLIONS)</i>	65
<i>FIGURE 7 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, 2010-2017 (\$ MILLIONS)</i>	65
OVERVIEW	65
<i>TABLE 20 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH</i>	68
<i>FIGURE 8 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH</i>	69
STRATEGIES IN METABOLOMICS RESEARCH	69
<i>TABLE 21 MAIN APPROACHES IN METABOLOMICS RESEARCH</i>	70
TARGETED ANALYSIS	70
METABOLIC FINGERPRINTING	70
METABOLITE PROFILING	71
TECHNOLOGIES AND ANALYTICAL APPROACHES IN METABOLOMICS RESEARCH	71
<i>FIGURE 9 SCHEMATIC REPRESENTATION OF EXPERIMENTAL METABOLOMIC APPROACHES</i>	72
IMPORTANCE OF BIOINFORMATICS RESOURCES FOR METABOLOMICS RESEARCH	72
APPLICATIONS OF METABOLOMICS RESEARCH	73
CHAPTER 6 GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS (REPORT BIO021D)	77
INTRODUCTION	77
STUDY OBJECTIVES	77
REASONS FOR DOING THIS STUDY	77
INTENDED AUDIENCE	77
SCOPE OF THE STUDY	78
METHODOLOGY	78
INFORMATION SOURCES	78
ABOUT THE AUTHOR	78
RELATED BCC RESEARCH REPORTS	79
SUMMARY	79
<i>TABLE 22 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	80
<i>FIGURE 10 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 (\$ MILLIONS)</i>	80
DEFINITIONS	81
HISTORY	81
<i>TABLE 23 EVOLUTION OF THERAPEUTIC PROTEINS</i>	82
PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS	83
PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY	83
PROTEIN THERAPEUTICS WITH SPECIAL TARGETED ACTIVITY	84
PROTEIN VACCINES	84
MANUFACTURING TECHNOLOGIES	84
NATURAL SOURCING AND EXTRACTION	85
<i>TABLE 24 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION</i>	86
<i>TABLE 25 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION</i>	86

<b>TOPIC</b>	<b>PAGE NO.</b>
MICROBIAL FERMENTATION	87
<i>TABLE 26 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION</i>	88
TRANSGENICS	88
<i>TABLE 27 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS</i>	89
MAMMALIAN CELL CULTURE	89
<i>TABLE 28 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE</i>	90
OTHER CELL CULTURE SYSTEMS	90
<i>TABLE 29 PROTEIN DRUGS MADE BY INSECT CELL CULTURE</i>	90
MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS	90
CYTOKINES	91
Colony-Stimulating Factors	91
Interferons	91
Interleukins	92
ANTIBODIES	92
BLOOD PRODUCTS	93
Alpha-1-Proteinase Inhibitor	93
Antihemophilic Factor	93
Antithrombin	94
C1 Esterase Inhibitor	94
Coagulation Factors	95
Immunoglobulins	95
Protein C	96
Thrombin	96
PEPTIDE ANTIBIOTICS	96
VACCINES	97
ENZYMES	98
Digestive Enzymes	98
Lysosomal Enzymes	99
Thrombolytic Enzymes	99
Other Enzymes	100
PEPTIDE HORMONES	100
Follicle-Stimulating Hormone and Luteinizing Hormone	101
Adrenocorticotropic Hormone	101
Growth Hormones	101
Erythropoietin	101
Insulin	102

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, THROUGH 2018 (\$ MILLIONS)	7
TABLE 2 MICRORNA DATABASES	11
TABLE 3 COMPUTATIONAL TOOLS FOR MIRNA TARGET PREDICTION	12
TABLE 4 GLOBAL PHARMACEUTICAL MARKET, MARKET SHARES BY REGION AND TOP COMPANIES (%/\$ MILLIONS/\$ BILLIONS)	16
TABLE 5 COMPARISON OF U.S. AND EUROPEAN PATENT SYSTEMS	23
TABLE 6 PATENT AND PATENT APPLICATION SEARCHES IN RNAI MARKETPLACE USING VARIOUS KEYWORDS, AS OF AUG. 2013	25
TABLE 7 PATENTS AND PATENT APPLICATIONS FOR RNAI DRUG COMPANIES, AS OF AUG. 2013	26
TABLE 8 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 (\$ MILLIONS)	33
TABLE 9 REPORT SCOPE	35
TABLE 10 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)	36
TABLE 11 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING	37
TABLE 12 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES	39
TABLE 13 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS	40
TABLE 14 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR	41
TABLE 15 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	47
TABLE 16 BIOINFORMATICS MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	56
TABLE 17 BIOINFORMATICS MARKET BY CATEGORY, THROUGH 2017 (\$ MILLIONS)	57
TABLE 18 BIOINFORMATICS MARKET BY APPLICATION, THROUGH 2017 (\$ MILLIONS)	59
TABLE 19 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, THROUGH 2017 (\$ MILLIONS)	65
TABLE 20 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH	68
TABLE 21 MAIN APPROACHES IN METABOLOMICS RESEARCH	70
TABLE 22 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	80
TABLE 23 EVOLUTION OF THERAPEUTIC PROTEINS	82
TABLE 24 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION	86
TABLE 25 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION	86
TABLE 26 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION	88
TABLE 27 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS	89
TABLE 28 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE	90
TABLE 29 PROTEIN DRUGS MADE BY INSECT CELL CULTURE	90

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 1 GLOBAL RNAI RESEARCH TOOL AND REAGENT, THERAPEUTIC, DIAGNOSTIC AND AGRICULTURE MARKET, 2011-2018 (\$ MILLIONS)	7
FIGURE 2 SIMPLIFIED SCHEMATIC REPRESENTATION OF THE RNAI MECHANISM	9
FIGURE 3 CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 (\$ MILLIONS)	33
FIGURE 4 BIOINFORMATICS MARKET BY REGION, 2011-2017 (\$ MILLIONS)	47
FIGURE 5 BIOINFORMATIC RELATIONSHIP TO 'OMIC TECHNOLOGIES	50
FIGURE 6 SYSTEMS BIOLOGY PRINCIPAL APPROACHES	52
FIGURE 7 GLOBAL MARKET FOR METABOLOMICS TECHNOLOGIES AND APPLICATIONS, 2010-2017 (\$ MILLIONS)	65
FIGURE 8 NUMBER OF PUBLICATIONS FROM 2000-2012 USING THE KEYWORD "METABOLOMICS" IN THE SEARCH	69
FIGURE 9 SCHEMATIC REPRESENTATION OF EXPERIMENTAL METABOLOMIC APPROACHES	72
FIGURE 10 GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 (\$ MILLIONS)	80